source
- Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thicketsIndustry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…
- China adds CAR-T therapy to national insurance list, slashing price to $40,000China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…